CVRx, Inc.
NASDAQ:CVRXMedical - Devices
+$0.11 today
- Market cap
- $69.79M
- Beta
- 0.77
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$2.00
Volume 0.37M
Average 0.30M
CVRX EBITDA Margin
EBITDA as a percentage of revenue.
CVRx, Inc.NASDAQ: CVRX
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -76.9%
EBITDA Margin was -76.9% in Q1 FY2026, up 21.3 pp from a year earlier. On a trailing-twelve-month basis it was -77.8%, up 9.1 pp year over year. Over 3 fiscal years it widened by 98.8 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -82.2% for the fiscal year ending Dec 2026, up from -82.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -76.9%-12.4 pp QoQ
- Last fiscal yearDec 2025
- -82.5%+24.5 pp YoY
- LTMMar 2026
- -77.8%+9.1 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +21.3 pp | +19.6 pp | -1.7 pp |
| 1 year | +24.5 pp | +0.3 pp | -24.3 pp |
| 3 years | +98.8 pp | +26.1 pp | -72.7 pp |
| 5 years | +63.8 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -82.5%
- Year-over-year change
- +24.5pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -82.5% | +24.5pp |
| FY2024 | 2024-12-31 | -107.0% | -8.5pp |
| FY2023 | 2023-12-31 | -98.6% | +82.8pp |
| FY2022 | 2022-12-31 | -181.3% | +130.1pp |
| FY2021 | 2021-12-31 | -311.4% | — |
EBITDA Margin vs competitors
How CVRX compares with its peers on the latest reported figures
- CVRX's LTM Mar 2026 EBITDA Margin of -77.8% is the 7th highest of the 10 companies compared; the peer median is -46.0%.
- Its year-over-year change of +9.1 pp is the 5th highest of 10, against a peer median of +5.1 pp.
- Over three fiscal years its change of +98.8 pp compares with a peer median of +16.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 51.1% | +104.6 pp | +15.5 pp | |
| LTM Mar 2026 | 18.5% | +0.7 pp | +1.2 pp | |
| LTM Mar 2026 | 0.5% | +5.1 pp | +18.3 pp | |
| LTM Mar 2026 | -39.8% | +16.3 pp | +70.4 pp | |
| LTM Mar 2026 | -46.0% | +3.6 pp | +16.5 pp | |
| LTM Mar 2026 | -58.4% | -27.4 pp | -3.0 pp | |
| LTM Mar 2026 | -77.8% | +9.1 pp | +98.8 pp | |
| LTM Mar 2026 | -198.5% | +73.8 pp | -1165.0 pp | |
| LTM Mar 2026 | -319.0% | -184.3 pp | +1328.5 pp | |
| LTM Dec 2025 | -376.3% | +15.0 pp | +506.1 pp | |
| Peer median (excluding CVRX) | -46.0% | +5.1 pp | +16.5 pp | |
Competitors are the stored peer set for CVRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 13.04M | 22.47M | 39.3M | 51.29M | 56.65M |
| Cost of Revenue | 3.64M | 5M | 6.26M | 8.33M | 8.31M |
| Gross Profit | 9.4M | 17.47M | 33.04M | 42.96M | 48.34M |
| Gross Margin | 72.1% | 77.8% | 84.1% | 83.8% | 85.3% |
| Research & Development | 7.5M | 9.95M | 11.63M | 11.13M | 11.13M |
| Selling, General & Admin | 27.86M | 50.05M | 64.51M | 91.32M | 88.47M |
| Operating Expenses | 35.36M | 60M | 76.14M | 102.45M | 99.61M |
| Depreciation & Amortization | 168K | 412K | 522K | 619K | 756K |
| EBITDA | (40.6M) | (40.74M) | (38.73M) | (54.89M) | (46.74M) |
| EBITDA Margin | -311.4% | -181.3% | -98.6% | -107.0% | -82.5% |
| Operating Income | (25.97M) | (42.53M) | (43.1M) | (59.49M) | (51.27M) |
| Operating Margin | -199.2% | -189.3% | -109.7% | -116.0% | -90.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.22M | 165K | 1.8M | 4.4M | 5.83M |
| Other Income / Expenses | (17.02M) | 1.21M | 2.05M | (420K) | (2.06M) |
| Income Before Tax | (42.99M) | (41.32M) | (41.05M) | (59.91M) | (53.32M) |
| Pre-Tax Margin | -329.8% | -183.9% | -104.5% | -116.8% | -94.1% |
| Income Tax Expense | 91K | 109K | 147K | 55K | (18K) |
| Net Income | (43.08M) | (41.43M) | (41.2M) | (59.97M) | (53.31M) |
| Net Margin | -330.5% | -184.4% | -104.8% | -116.9% | -94.1% |
| EPS (Basic) | (2.11) | (2.02) | (1.99) | (2.65) | (2.04) |
| EPS (Diluted) | (2.11) | (2.02) | (1.99) | (2.65) | (2.04) |
| Weighted Avg Shares | 20.72M | 20.51M | 20.7M | 22.6M | 26.08M |
| Weighted Avg Shares (Diluted) | 20.72M | 20.53M | 20.75M | 22.6M | 26.08M |
CVRx, Inc.
NASDAQ:CVRX
Intrinsic Alpha fair value
Locked
Current Price
$2.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.